Preventing Tumor Progression in Women with High-Risk DCIS

Project: Research project

Project Details


Rationale: We reason that a TSEC agent that reverts pro-tumorigenic effects in fibroblasts in vitro may prove beneficial in women newly diagnosed with DCIS, thus offering novel therapeutic opportunities. Experimental design: We will provide five slides from the pre- and post-intervention biopsies in 20 patients from a pilot trial aimed at evaluating the benefit of a TSEC agent (Duavee) in a prospective randomized cohort of women diagnosed with DCIS and treated with the TSEC or Placebo for 28+/-7 days between their initial diagnosis of DCIS and their surgical resection. The combined information gained from the trial and the proposed study will provide invaluable insights into the therapeutic potential of TSEC in women diagnosed with DCIS.
Effective start/end date9/1/168/31/19


  • University of California, San Francisco (9699sc A1//22OB-0032)
  • University of California, Office of the President (9699sc A1//22OB-0032)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.